JAMA Medical News Clinical Highlights From the American Diabetes Association’s Scientific Sessions
13 snips
Jul 26, 2024 Dr. Robert Gabbay, an endocrinologist and chief scientific officer at the ADA, shares insights on groundbreaking diabetes research. He discusses impressive advancements in weight loss medications and the innovation of GLP-1 receptor agonists for kidney health and diabetes prevention. The talk highlights the new potential for inhaled insulin and the importance of continuous glucose monitoring technology. Dr. Gabbay also emphasizes the need for combining medication with lifestyle changes, all amidst exciting collaborations between academia and startups.
AI Snips
Chapters
Transcript
Episode notes
Terzepatide for Sleep Apnea
- Terzepatide significantly reduces sleep apnea scores by 55%.
- This suggests a potential medical treatment for obstructive sleep apnea, a condition often untreated due to CPAP intolerance.
GLP-1s for Kidney Disease
- The FLOW trial showed a 24% reduction in chronic kidney disease progression using a GLP-1 receptor agonist.
- This offers a new treatment option alongside existing therapies like ACE-ARB, SGLT2 inhibitors, and phenarinone.
Semaglutide and Diabetes Prevention
- Semaglutide in the SELECT trial showed a 73% reduction in type 2 diabetes progression in individuals without diabetes.
- This suggests potential beyond weight loss, possibly preserving beta cells and insulin secretion.